Many organic impurities, such as nitrosamines, are known to be harmful to human health. Therefore, regulatory bodies and government set strict limits to protect us all. Even in small quantities, pharmaceutical impurities can have serious negative health impacts and influence the behaviour and efficacy of a drug. Organic impurities fall into a number of categories.

Over the last year we have seen a substantive shift in terms of the type / nature of N-Nitrosamines we have seen, moving from the process related small simple dialkyl N-Nitrosamines seen in Valsartan, such as NDMA / NDEA, to API like N-Nitrosamines.  Our knowledge is such that we now have a good understanding of